+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Ixekizumab"

From
Interleukin Inhibitors Market Report 2025 - Product Thumbnail Image

Interleukin Inhibitors Market Report 2025

  • Report
  • April 2025
  • 250 Pages
  • Global
From
From
From
Psoriasis Market Report 2025 - Product Thumbnail Image

Psoriasis Market Report 2025

  • Report
  • April 2025
  • 175 Pages
  • Global
From
From
From
From
From
From
From
From
Psoriasis Treatment Market Report and Forecast 2024-2032 - Product Thumbnail Image

Psoriasis Treatment Market Report and Forecast 2024-2032

  • Report
  • July 2024
  • 200 Pages
  • Global
From
Loading Indicator

Ixekizumab is a monoclonal antibody used to treat immune disorders. It is a type of biologic drug, which is a medication derived from living cells. It works by blocking the action of a protein called interleukin-17A (IL-17A), which is involved in inflammation. Ixekizumab is used to treat psoriasis, an autoimmune disorder that causes red, scaly patches on the skin, and psoriatic arthritis, a type of arthritis that affects people with psoriasis. It is also used to treat ankylosing spondylitis, a type of arthritis that affects the spine. Ixekizumab is administered as an injection under the skin. It is available in both brand-name and generic forms. It is typically used in combination with other medications, such as methotrexate or corticosteroids. Ixekizumab is manufactured by several companies, including Eli Lilly, Amgen, and Novartis. It is also available as a generic drug from several generic drug manufacturers. Show Less Read more